




































ARTICLE IN PRESSG ModelEAP-4316; No. of Pages 13
Health Policy xxx (2020) xxx–xxx
Contents lists available at ScienceDirect
Health  Policy
j our na l ho me  page: www.elsev ier .com/ locate /hea l thpol
ricing  of  in-patent  pharmaceuticals  in  the  Middle  East  and  North
frica:  Is  external  reference  pricing  implemented  optimally?
anos  Kanavos a,∗,  Bregtje  W.  Kamphuis a,  Anna-Maria  Fontrier a, Georgia  Colville  Parkin a,
hadi  Saleh b,  Kasem  S.  Akhras c
Department of Health Policy, Medical Technology Research Group - LSE Health, London School of Economics and Political Science, Houghton Street,
ondon WC2A 2AE, United Kingdom
Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
Government Affairs & Market Access, MEA  Region, AstraZeneca FZ LLC, 2ndFloor Block D Building 27, Dubai Healthcare City, P.O. Box 5505070, Dubai,
nited Arab Emirates
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 5 January 2020
eceived in revised form 29 July 2020








a  b  s  t  r  a  c  t
In  this  paper  we  outline  and  compare  pharmaceutical  pricing  policies  for in-patent  prescription  pharma-
ceuticals  with  emphasis  on  external  reference  pricing  (ERP)  in eleven  countries  across  the  Middle  East
and  North  Africa  (MENA)  region  and  explore  possible  improvements  in their pricing  systems.  Primary
and  secondary  evidence  was  used  to inform  our  analysis.  Comparative  analysis  of  ERP systems  across
countries  followed  an  analytical  framework  distilling  ERP  into  twelve  salient  features,  while  ERP  system
performance  was  benchmarked  against  a framework  of  best  practice  principles  across  (a) objectives  and
scope, (b)  administration  and  operations,  (c)  methods  used,  and  (d)  implementation.  Results  suggest  that
ERP  is the  dominant  pricing  method  for  in-patent  pharmaceuticals.  Although  several  good  practice  cases
were identified,  none  of  the eleven  countries  satisfy  all  best practice  principles.  ERP basket  sizes  vary  sig-
nificantly  and  are  commonly  composed  using  geographical  proximity  and  low-price  countries  as  criteria.
Nine  countries  do not  use  the  mean  or median  prices,  but resort  to  using  the  lowest.  Exchange  rate  fluc-
tuations  are  routinely  used  to  arrive  at price  reductions  in local  currency.  Significant  opportunities  exist
for MENA  countries  to develop  their  ERP  regimes  to achieve  greater  compliance  with  best  practice  princi-
ples. Over  the short-term,  incremental  changes  could  be implemented  to several  ERP salient  features  and
can be  achieved  relatively  easily,  thereby  enhancing  the  functionality  and  performance  of national  ERP
systems.  Countries  in  the  region  can  also  focus  on  the  development  of explicit  value assessment  systems,
and  minimize  their  dependence  on  ERP  over  the longer-term.
©  2020  The  Author(s).  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under  the  CC. Background
The Middle East and North Africa (MENA) region stretches
rom Morocco to Oman and includes countries with diverse eco-
omic status and fragmented health care systems. The health care
nvironment in the region is subject to considerable change and
pidemiological (rising prevalence of non-communicable disease)Please cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
s well as economic and fiscal pressure (rising health care costs
nd coverage issues). Total health expenditure ranges between 3.1%
nd 7.4% of GDP ($435 to $3,900 per capita in purchasing power
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parity (PPP) terms) (World Bank, 2019), but government health
expenditure ranges between 1.25% and 4.98% of GDP (Fig. 1). Out-
of-pocket spending, captured by the difference between total and
government health spending, remains significant. Pharmaceutical
spending ranges between 11% and 49% of total health expenditure
across the region (Fig. 1). Health care systems are fragmented, with
many actors involved in the purchasing of prescription medicines,
delivery of health care and reimbursement mechanisms (Kaló, et al.,
2015; Qarain et al., 2009; Business Monitor International (BMI),
2017a, 2017b, 2017c, 2017d, 2017e, 2017f, 2017g).
Within this challenging context, pharmaceutical policy is
increasingly subject to scrutiny, with a focus explicitly on con-
trolling pharmaceutical costs given its substantial contribution to pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
overall health expenditure. External reference pricing (ERP), the
practice of one country using the list price of a pharmaceutical
product in one or more countries to arrive at a reference price for
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. Health care (total and public1) and pharmaceutical (total2) expenditure in MENA countries.
Sources: (World Bank, 2019; Business Monitor International (BMI), 2017a, 2017b, 2017c, 2017d, 2017e, 2017f, 2017j, 2017k, 2017l, Hammad, 2016; Kanavos et al., 2018).






































With regards to pharmaceutical expenditure, a breakdown into public vs. priva
ut-of-pocket) pharmaceutical expenditure in the total is thought to be high; Egyp
pending, relative to total pharmaceutical spending, at 70% (Kanavos et al., 2018).
etting or negotiating the product price in its territory, is now the
ost commonly used pricing policy across the region for in- and
ff-patent pharmaceuticals.
Experimental studies on the impact of ERP on price levels and
harmaceutical savings are very limited, for a number of reasons
ncluding difficulties in isolating the impact of ERP from that of
ther policies or practices. Available evidence on the performance
r comparative assessment of ERP systems in the region is limited.
n general, ERP is straightforward, particularly for resource-limited
ountries. However, unavailable price information or issues with
btaining transaction prices necessary to implement ERP increase
omplexity (World Health Organization, 2015). As a result of using
RP, countries striving for lower prices may  experience availabil-
ty issues or access delays for certain prescription pharmaceuticals
Kaló et al., 2015; Espin et al., 2011; Gill et al., 2019; Kanavos et al.,
010; Leopold et al., 2012; Fontrier et al., 2019; Kanavos et al.,
020). This is due to launch sequencing or launch delays initiated by
anufacturers, strategically launching in countries where higher
rices can be achieved (Espin et al., 2011). ERP may  lead to price
eductions over time, and this depends on its design characteris-
ics in each setting (Leopold et al., 2012; Håkonsen et al., 2009),
hough this finding may  not hold in lower and middle-income
ountries (LMICs). Indeed, earlier work in the MENA region, con-
luded ERP may  result in higher pharmaceutical prices in LMICs
elative to prices for non-pharmaceutical services, although larger
opulation size, reference baskets larger than five countries and the
se of the lowest price in the basket significantly reduce relative
harmaceutical prices (Kaló, et al., 2015).
Considering the evidence gap in MENA ERP systems and their
mplementation, the objective of this paper is twofold: First, given
he effects of ERP are often linked to design issues and implemen-Please cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
ation, we analyse the key features of ERP systems in the MENA
egion. Second, we critically appraise the performance of ERP sys-
ems in MENA countries across measures of their (i) objectives and
cope, (ii) administration and operations, (iii) methods used andstly out-of-pocket) expenditure is not available, but the share of private (chiefly
 example, has one of the highest shares of private (out-of-pocket) pharmaceutical
(iv) implementation based on an methodological framework that
captures salient features of ERP (Sullivan et al., 2018).
2. Analytical framework
2.1. Why  regulate in-patent pharmaceuticals?
Regulating in-patent pharmaceutical markets is a response
to the imperfections of the market for pharmaceuticals com-
prising multiple stakeholders (payer-manufacturer-prescriber-
consumer/patient) with different interests and objectives and the
predictions of monopoly pricing or monopolistic behaviour by
innovators. As monopolistic price-setting by the innovator may
lead to poor market coverage, a regulator may either impose a
price ceiling on new product prices or use an objective value assess-
ment mechanism to inform price-setting and, through that, arrive
at a maximum acceptable price. Where decision-makers struggle
to set a suitable entry price below the monopoly price, do not have
the capability to assess the value of new pharmaceutical products
based on objective criteria and arrive at a price based on an ex ante
determined willingness to pay (WTP) threshold or a price negotia-
tion, they often resort to referencing prices from other settings iin
an attempt to ensure that the resulting pharmaceutical prices in
their territory are not excessive and contribute to macroeconomic
efficiency.
2.2. Salient features of ERP systems
Based on evidence from primary and secondary sources (Gill
et al., 2019; Fontrier et al., 2019; Kanavos et al., 2020) ERP can be
decomposed into twelve key system features, as follows: (a) the pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
role of ERP, defined by its use in informing pricing and/or reim-
bursement; (b) whether ERP occupies a main or supplementary
role in pricing decisions (dominant pricing method vs. used in
parallel with other criteria); (c) whether ERP occupies a main or
 IN PRESSG ModelH




























































Best practice principles of External Reference Pricing (ERP)
No. EPR best practice principle
1 The objectives of ERP systems should be clear and align with
health system objectives
2  ERP systems should focus on in-patent products considered for the
purposes of coverage, pricing and reimbursement decisions
3  Prices developed via ERP do not override HTA conclusions or VBP
approaches
4 The ERP system should have administrative simplicity and
transparency
5 Stakeholders should participate in design and review of ERP
system
6 Stakeholders should be able to appeal regulator decisions
7  Reference countries should be selected based on similarities in
economic status and health system objectives
8 International implications of ERP implementation should be
considered
9  Publicly available ex-factory prices should form the basis of the
ERP system
10 The mean of prices in reference countries should be used
11  ERP systems should respect the patent status of products it covers
based on intellectual property (IP) rights provisions that prevail in
referent country
12 ERP formula should avoid the impact of exchange rate volatility
13 Price revisions should be kept to a minimum and should be carried
out  consistently to avoid the perception of opportunistic behaviour
14 ERP-based prices should be aligned with other tools used when
negotiating reimbursement
Source: (Gill et al., 2019; Fontrier et al., 2019; Kanavos et al., 2020; Sullivan et al.,
2018).
Table 2
Search strategy for the identification of literature on ERP in MENA countries.
“Price Regulation” OR “Pharmaceutical Regulation” OR “Regulation” OR
“Price legislation” OR “Price legislations” OR “Price controls” OR “Price
control” OR “Pharmaceutical Policy” OR “Policy” OR “Pricing” OR
“External Reference Pricing” OR “External Price Referencing” OR
“International Price Comparisons” OR “International Reference Pricing”
OR “International Price Referencing” OR “Price Harmonization” OR  “Price
Unification” OR “Unified Pricing” OR “Reference Pricing” OR “Price
Referencing”
AND
"Drug" OR "drugs" OR "medicine" OR "medicines" OR "pharmaceutical"
OR  "pharmaceuticals"
AND
“Middle East” OR “North Africa” OR "GCC" OR “Gulf Cooperation Council”
OR  "Algeria" OR "Egypt" OR "Morocco" OR "Lebanon" OR "Jordan" ORARTICLEEAP-4316; No. of Pages 13
P. Kanavos et al. / Heal
upplementary role in reimbursement decisions; (d) the number
f countries in the ERP basket; (e) the basket country selection
riteria; (f) the price used to inform pricing decisions (average,
edian, lowest or other); (g) the information sources used in iden-
ifying and validating prices (publicly available vs. confidential); (h)
he basis for reference price calculation (ex-factory, wholesale or
etail); (i) whether ERP covers only in-patent, or also off-patent and
eneric pharmaceuticals; (j) whether pharmaceutical patent expiry
n reference countries and concomitant price reductions, are used
s means to initiate further price reductions in referent countries;
k) the exchange rate used to translate prices from foreign to local
urrency and how exchange rate volatility is dealt with; and (l)
he frequency of price revisions (e.g. at launch only, annual, more
requent).
.3. Performance assessment of ERP systems
Depending on a country’s objectives and goals, ERP systems are
esigned to contain costs and encourage low prices. To evaluate
he systems in the MENA region, an assessment of the alignment
f national ERP systems to best practices in the design, introduc-
ion and implementation of ERP was performed using an analytical
ramework comprising good practice principles from the literature
World Health Organization, 2015; Gill et al., 2019; Kanavos et al.,
010; Fontrier et al., 2019; Kanavos et al., 2020; Sullivan et al.,
018).
Best practice principles expand on the salient features of ERP
ystems to include other factors pertaining to administration of
nd stakeholder participation in the system, covering issues relat-
ng four key areas of policy, notably, (i) objectives and scope, (ii)
dministration and operations, (iii) methods used, and (iv) imple-
entation. As part of the objectives and scope, principles include
a) the design of a system in line with health system objectives,
b) the focus on in-patent pharmaceuticals, and (c) the likelihood
f introducing an explicit value assessment system in the future.
or administration and operations,  we consider whether systems (a)
re administratively simple and transparent, (b) allow stakeholders
o participate in its design and review, and (c) have established a
traightforward process and opportunities for stakeholder appeals.
RP methods should satisfy a number of criteria: (a) select ERP
eference countries based on similarities in economic status and
ealth system objectives, ((b) take international implications of
RP into consideration, (c) methods to perform calculations should
e based on publicly available ex-factory prices, (d) the mean or
edian price of the basket should be selected, (e) price informa-
ion should be based on available information and employ methods
o reduce exchange rate volatility, and (f) referencing prices of
ff-patent pharmaceuticals within reference countries where on-
atent pharmaceuticals have lost their patent status should be
voided. Implementation of ERP should (a) note that price revisions
hould happen on a scheduled, but infrequent, basis, with a pub-
icly available revision schedule and (b) consider that when ERP is
sed to set prices alongside other methods of value determination,
he system should consider the relative importance of ERP in deter-
ining prices and how ERP aligns with such tools. A summary of
est practice principles is shown in Table 1.
. Methods
The study relies on both primary and secondary data collec-
ion. In terms of secondary data, a systematic literature review wasPlease cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
onducted in accordance with CRD guidelines (Center for Reviews
nd Dissemination, 2008) to identify a relevant bibliography on
RP in peer-reviewed and grey literature. Eleven MENA coun-
ries (Algeria, Bahrain, Egypt, Jordan, Kuwait, Lebanon, Morocco,"Saudi Arabia" OR "Kuwait" OR “United Arab Emirates” OR "UAE" OR
"Qatar" OR "Bahrain" OR "Oman"
Oman, Qatar, the Kingdom of Saudi Arabia (KSA), and the United
Arab Emirates (UAE)) were selected for study given all belong to
the same geographical area and use ERP to inform price-setting
of in-patent pharmaceuticals (Kaló et al., 2015; Business Monitor
International (BMI), 2017f, 2017h, 2017i; Abuelkhair et al., 2012;
Hammad, 2016; Khan et al., 2015; Mohamed, 2014; Ministry of
Health of the Sultanate of Oman and World Health Organization,
2011; Alrasheedy et al., 2017; Anonymous, 2018). We  used (a) the
endpoints included in the analytical framework to perform a map-
ping of ERP systems in the study countries and (b) the performance
assessment endpoints based on the best practice principles to arrive
at an assessment of their performance on a comparative basis.
ProQuest, Web  of Science, Medline, EconLit and CINAHL were
searched using keywords, including synonyms and different phras-
ings of “ERP and pharmaceuticals” and study country names
(Table 2). The search was limited to English articles published
between 1 January 2000 and 31 May  2020. The search was restricted pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
to keywords presented within document titles only, to limit the
number of irrelevant papers. All documents were downloaded and
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rticles were initially screened by two of the authors (BK and
C) for relevance by title and abstract. Papers with relevant titles
nd/or abstracts were downloaded for further examination of the
ain text for relevance against the selected endpoints. Publica-
ions providing information on at least one of the endpoints were
ncluded, and using an excel spreadsheet, two of the authors (BK
nd GC) extracted the relevant information against each endpoint.
 targeted search of official documents from Health Ministries and
egulatory authority websites in the countries of interest, the World
ealth Organization (WHO), the World Bank and other grey lit-
rature sources, including market sources, were also reviewed to
dentify further information on the endpoints. Additionally, a tar-
eted Google search was performed, the results of which were
mported in the same spreadsheet, where the relevant text was
xtracted and sorted against the study endpoints.
Primary data was collected through a survey (May - September
018) to validate secondary data findings and obtain a practical
iew of the current operating environment in the study countries.
ver 80 experts and stakeholders were contacted via email, includ-
ng government officials, industry executives, and expertes from
egulatory authorities, insurance organizations, pharmacy depart-
ents and procurement agencies. Survey questions were designed
ccording to the salient features and performance indicators iden-
ified, and related to: (a) details of pricing policies and price setting;
b) key features of the ERP system in each country; and (c) evidence
f ERP impact within and across countries, notably on affordabil-
ty, availability, barriers, and regional or international implications.
esponses were subsequently coded thematically to extract key
oncepts and trends throughout the region. In addition to complet-
ng the survey, all respondents were invited to interview guided by
emi-structured interview guides, covering aspects of ERP features
nd performance, with content tailored to gather information on
he gaps, barriers and bottlenecks identified per country and fur-
her detail on practical issues resulting from ERP. A final round of
riangulation took place during a face-to-face meeting in Dubai in
eptember 2018 between the lead author (PK) and decision-makers
rom the study countries aiming to validate the original findings
ith experts from study country competent authorities.
In order to present our findings on ERP systems in eleven coun-
ries, we report our findings on the design and implementation
f these systems along the framework developed on salient fea-
ures of ERP, and subsequently assess the performance of these
ystems against the best practice principles outlined in Table 1.
here clear evidence of adherence to a principle was identified,
ountry performance was scored positively, and where evidence
f non-adherence to each principle was identified, performance
as scored as either not or only partially fulfilling the principle.
his analysis was  followed by results on the performance of each
ountry in line with the ERP best practice principles.
. Results
.1. Available evidence on ERP in MENA
Of 368 identified studies, 28 were included and reviewed (Fig. 2),
ncluding peer-reviewed literature (n = 6), grey literature (n = 20)
nd legislative documents (n = 2). Sources covered countries either
ndividually or as a region and provided information on the salient
eatures of ERP or its implementation. One or more sources were
ound for most countries, except Algeria where no relevant litera-
ure was identified.Please cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
Through the survey and follow-up interviews, ten experts con-
ributed material and insights on the salient features of ERP systems
nd practical implementation issues. No primary data was  obtained
or Oman, but evidence was obtained through direct contact with PRESS
cy xxx (2020) xxx–xxx
the country’s governmental sources of the Ministry of Health
(MoH).
4.2. Salient features of ERP regimes for in-patent pharmaceuticals
in the MENA region
Table 3 highlights the key features of ERP systems across the
region. ERP occupies a main role in pricing of in-patent, off-patent,
imported generic and biosimilar pharmaceuticals in Algeria and
may  be used as a guide for reimbursement (Business Monitor
International (BMI), 2017c; Anonymous, 2018). The Algerian ERP
basket comprises nine countries, including the product’s country-
of-origin (COO) (Business Monitor International (BMI), 2017c;
Holtorf et al., 2019). Countries are selected based on geographical
proximity, comparable GDP levels, the product’s COO, socioeco-
nomic factors, such as universal healthcare systems, and countries
with affordable European prices (Anonymous, 2018). The ERP sys-
tem relies on ex-factory and retail prices in the reference countries
with information obtained from manufacturers and public sources
(Anonymous, 2018; Holtorf et al., 2019). The reference price is the
lowest basket price and is revised every five years (except for locally
manufactured pharmaceuticals), or in response to price changes
in basket countries (Anonymous, 2018; Holtorf et al., 2019). Price
adjustments are possible in response to exchange rate fluctuations
by using the current exchange rate (Anonymous, 2018; Holtorf
et al., 2019).
In Bahrain, ERP is used for the pricing of in-patent pharma-
ceuticals; it may  be used for pricing of generics, together with
other tools such as internal reference pricing (IRP) or price capping
(Anonymous, 2018). In-patent pharmaceutical prices are set con-
sidering the price in the COO, ex-factory prices, cost, insurance and
freight (CIF) prices in the Gulf Cooperation Council (GCC) region,
the therapeutic significance of the drug, drug prices found in offi-
cial pricing references, prices of similar drugs in Bahrain and, if
available, pharmacoeconomic studies (Al Abbasi and Al Jalahma,
2017; Anonymous, 2018; Holtorf et al., 2019). The reference bas-
ket comprises at least six countries, which are selected based on
geographical proximity and COO (Al Abbasi and Al Jalahma, 2017;
Anonymous, 2018) and the reference price is the lowest in the bas-
ket (Holtorf et al., 2019). Price revisions can take place during the
registration period of a drug (typically 5 years) and during reg-
istration renewal (Al Abbasi and Al Jalahma, 2017; Holtorf et al.,
2019). During the registration period, price revisions are performed
if: (a) there is a price reduction for the product in the COO; or (b)
the product has been registered with a lower price in another GCC
country; or (c) there is a change in the manufacturing site; or (d)
at the manufacturer’s request (Al Abbasi and Al Jalahma, 2017).
Price adjustments are possible to account for currency fluctuations,
although all CIF prices are set in USD to prevent such fluctuations
(Al Abbasi and Al Jalahma, 2017; Anonymous, 2018).
The Egyptian ERP version relies on a basket of 36 countries (Kaló,
et al., 2015; Qarain et al., 2009; Mohamed, 2014; Holtorf et al., 2019;
Wanis, 2015). Country selection is based on geographical proxim-
ity, comparable GDP levels and the COO, and relies on retail prices
obtained from manufacturers and public sources (Kaló, et al., 2015;
Anonymous, 2018; Holtorf et al., 2019). The reference price is the
lowest in the basket, and regulation suggests the price is revised
every five years or in response to currency fluctuations (if these
are +/- 15% in a year), or at manufacturers’ request, limited to a
maximum of 5% of their product portfolio per year (Kaló, et al.,
2015; Mohamed, 2014; Anonymous, 2018; Holtorf et al., 2019; pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
Wanis, 2015). No price adjustments are allowed to compensate
for inflation but can occur in light of exchange rate fluctuations
(Qarain et al., 2009; Business Monitor International (BMI), 2017a;












































































































Salient features of ERP in the MENA region.
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Main × × × 36 AR, AT, BE, BH,
CA, CH, CY, DE,
DK, DZ, ES, FI,
FR, GR, HU, IE,
IN, IR, IT, JO, JP,
KSA, KW,  LB,
MA,  NL, NO, OM,
PH, PL, PT, SD,
























√ √† - 18 AT, AU, BE, CY,
CZ, ES, FR, GR,
HR, HU, IE, IT,
NL, NZ, PT, UK +

































































































































































































√ × × 15 BE, BH, CH, ES,
FR, IT, JO, KSA,
KW,  OM,  PT, QA,













√‡ √‡ √— 7 BE, ES, FR, KSA,
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Main × √‡* √ 30 AR, AU, BE, BH,
CA, CH, CY, DE,
DK, DZ, EG, ES,
FR, GR, HU, IE, IT,
JO, JP, KR, KW,
LB, NL, NZ, OM,






































































































































































Main × √† × 18 AT, BE, BH, CA,
CH, DE, DK, ES,
FI, FR, IE, IT, KSA,

























1 Figure for number of basket countries includes COO.
2  Price-cut is mandatory if BE, ES, FR or UK, is the lowest price in the basket (30).
3  The figure does not include ‘other countries’ as specified in the latest version (April 2017) of the Pricing Guideline from the Bahraini National Health Regulatory Authority (NHRA). Primary data collection suggests that the basket
of  countries considered is identical to the Saudi basket.
4  If the drug is marketed in less than five countries, pricing should either follow a comparative study between the product in question and its therapeutic alternatives, or be set as the least of the prices in those five countries (32).
5  If the product is not priced in all countries, the median price is taken in no less than four countries, as available (30, 33).
6  Pricing criteria also include countries where prices can be found in official references (e.g. BNF), but these are not specified. An additional price-setting criterion includes prices of other drugs in the same pharmacological group.
7  The Jordanian EPR basket comprises 16 countries. Country of origin and Saudi Arabia are added as potential pricing options, rather than as explicit basket countries, as they are included in four pricing options for the lowest
price  (Price in COO, in KSA, across basket, or export price).
8 Primary evidence reported the Kuwaiti basket comprises a total of 30 countries of which the average is used to extract the reference price (30). The five countries included in the table (and the lowest price thereof) relate to the
GCC  basket, which is used routinely in price setting.
9 The COO is included in the basket when the price is different and when the price is equal to ex-factory price of COO if not launched in the basket countries (30).
10  The average price of the basket is considered for existing products, contrary to the lowest price which is considered for new pharmaceuticals (30).
11  Pricing for in-patent pharmaceuticals may rely on ERP and, if available, the therapeutic significance of the product, pharmacoeconomic studies of the product and prices of similar medicines that are registered in KSA and the
proposed price by the manufacturer may also be used.
12  Pricing for in-patent pharmaceuticals also relies on IRP.
13 Evidence on the cost-effectiveness of the pharmaceutical is required to inform pricing decisions for in-patient pharmaceuticals for instances where the product is only available in COO and three of the preselected reference
countries.
14  ERP use for pricing of generics is restricted to imported or partially locally manufactured generics, and does not apply to wholly locally manufactured products.
15  ERP use for the pricing of generics is for prices in the Omani private sector.
Key:
√
=  yes / used.
× = no / not used.
- = no evidence.√
— = Used as a reference price/guide and/or not necessarily in a systematic way.√†  = used solely for imported generics and/or biosimilars.√
*  = used solely for locally manufactured generics and/or biosimilars.√‡  = used solely when the originator is not present in the home market.
Country key: AR (Argentina); AT (Austria); AU (Australia); BE (Belgium); BH (Bahrain); CA (Canada); CH (Switzerland); COO (Country-of-Origin); CY (Cyprus); CZ (Czech Republic); DE (Germany); DK (Denmark); DZ (Algeria);
EG  (Egypt); ES (Spain); FI (Finland); FR (France); GR (Greece); HR (Croatia); HU (Hungary); IE (Ireland); IN (India); IR (Iran); IT (Italy); JO (Jordan); JP (Japan); KR (South Korea); KW (Kuwait); LB (Lebanon); MA  (Morocco); NL
(Netherlands); NO (Norway); NZ (New Zealand); OM (Oman); PH (Philippines); PL (Poland); PT (Portugal); QA (Qatar); KSA (Saudi Arabia); SD (Sudan); SE (Sweden); TN (Tunisia); TR (Turkey); UAE (United Arab Emirates); UK
(United  Kingdom).
Source: Adapted by the authors from the findings of both primary and secondary data collection presented in the results section.
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Fig. 2. PRISMA flowchart for Systematic
ERP plays a main role in price setting of in- and off-patent phar-
aceuticals and imported generics in Jordan, where the Jordan
rug and Food Administration (JFDA) selects the lowest price out of
a) the price in the COO, (b) the price in KSA and (c) the median price
f a basket of 16 countries) (Kaló et al., 2015; Qarain et al., 2009;
ammad, 2016; Anonymous, 2018; El-Dahiyat and Curley, 2017).
he complete reference basket, therefore, is made up of a total of
8 countries (Kaló et al., 2015; Qarain et al., 2009; Business Monitor
nternational (BMI), 2017g; Espin et al., 2011; Hammad, 2016;
oltorf et al., 2019; El-Dahiyat and Curley, 2017). No specific cri-
eria are used to select basket countries (Anonymous, 2018). Retail
nd ex-factory prices supplied by manufacturers and found in pub-
icly available sources are used to inform price setting (Kaló et al.,
015; Espin et al., 2011; Holtorf et al., 2019; El-Dahiyat and Curley,
017). Price revisions occur as follows: (a) two years after initial
egistration and every five years thereafter (Kaló et al., 2015; Qarain
t al., 2009; Anonymous, 2018; El-Dahiyat and Curley, 2017); (b)
f changes in currency exchange rates take place in the reference
asket including the COO; or (c) if a price reduction takes place
n KSA (Business Monitor International (BMI), 2017b; Anonymous,
018; Kanavos et al., 2018). Price adjustments due to exchange rate
uctuations take place quarterly (Anonymous, 2018; Holtorf et al.,
019).
ERP is used as a main price setting policy in Kuwait, where the
asket comprises five countries (Anonymous, 2018), all from the
CC, although pricing guidance may  be based on a larger basket
f 30 countries. Basket countries are selected based on socio-
conomic and geographical criteria. Price data is based on CIF and
etail prices provided by manufacturers and available in the public
omain (Kaló, et al., 2015; Anonymous, 2018; Holtorf et al., 2019).
eference prices are the lowest in the basket and may  be revised
ue to price changes in key basket countries or one of the GCC coun-
ries (Kaló et al., 2015; Anonymous, 2018; Holtorf et al., 2019). A
xed exchange rate based on the average over the past six months,
s used by the MoH  to address potential exchange rate fluctuations
Anonymous, 2018).Please cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
ERP plays a main role in price setting in Lebanon for in- and off-
atent pharmaceuticals, where the basket comprises 15 countries
Business Monitor International (BMI), 2017d; Holtorf et al., 2019;ture Review of ERP in the MENA region.
Abdel Rida et al., 2019). No specific criteria are used to select basket
countries (Anonymous, 2018). Prices are based on CIF, wholesaler
and retail prices in basket countries as provided by the manufac-
turer (Kaló et al., 2015; Espin et al., 2011; Anonymous, 2018; Holtorf
et al., 2019). The reference price is the lowest in the basket and can
be revised every five years or when prices change in key basket
countries (Kaló, et al., 2015; Anonymous, 2018; Holtorf et al., 2019).
Price adjustments are possible to account for exchange rate fluc-
tuations every fifteen days (Business Monitor International (BMI),
2017d; Anonymous, 2018; Holtorf et al., 2019; Ammar, 2009).
ERP plays a pivotal role in Morocco’s pricing strategy of in-
& off-patent pharmaceuticals and generic pharmaceuticals when
the originator product is not present in the Moroccan market
(Anonymous, 2018); reference prices are used as a guide for reim-
bursement. The basket references seven countries including the
COO (Business Monitor International (BMI), 2017i). Geographical
proximity and the COO are the main criteria for basket country
selection (Anonymous, 2018). ERP uses ex-factory prices in bas-
ket countries obtained from manufacturers and publicly available
sources. The reference price is the lowest in the basket and can be
revised every five years. Price revisions occur on a number of occa-
sions, including (a) the loss of market exclusivity by the originator,
(b) exchange rate fluctuation by more than 10%, (c) when there is a
change in the pharmaceutical formula or packaging, (d) on the basis
of the result of annual benchmarking in the reference countries,
or (e) when prices change in the basket countries (Anonymous,
2018).
ERP is used as a main tool for price setting for both in-patent,
off-patent and generic pharmaceuticals in Oman, though prices
can also be set based on prices in the same therapeutic group and
prices in official reference tools, such as the British National For-
mulary (Ministry of Health of the Sultanate of Oman and World
Health Organization, 2011). The ERP basket consists of at least six
countries, with the reference price being the lowest (Espin et al.,
2011; Ministry of Health of the Sultanate of Oman and World Health
Organization, 2011; Holtorf et al., 2019). The ERP system is based pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
on ex-factory, CIF, wholesale, and retail prices provided by manu-
facturers (Business Monitor International (BMI), 2017e). Prices are
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In Qatar ERP is the key tool informing in- and off-patent pharma-
eutical pricing decisions and is used as a guide for reimbursement
Anonymous, 2018; Abdel Rida et al., 2019). The Qatari basket is
mall, referencing five countries including the COO (Anonymous,
018). Basket countries are identified through geographical prox-
mity to Qatar (Anonymous, 2018). CIF and retail prices are obtained
hrough manufacturers and access to GCC CIF prices (Kaló et al.,
015; Anonymous, 2018; Holtorf et al., 2019). The reference price
s the lowest in the basket and prices are revised when changes
n key basket countries occur (Kaló et al., 2015; Business Monitor
nternational (BMI), 2017f; Holtorf et al., 2019). All CIF prices are
et in USD to prevent currency fluctuations (Anonymous, 2018).
ERP is the key tool informing price-setting for pharmaceuticals
n KSA and may  be used in reimbursement. The following informa-
ion informs pricing decisions: (i) ex-factory and wholesale price in
OO; (ii) retail prices in COO and other countries where the product
s marketed; (iv) CIF price to KSA in the COO currency; (v) CIF prices
o countries in which the product is marketed; and, if available: (vi)
he price in official pricing sources; (vii) product therapeutic sig-
ificance; (viii) relevant pharmacoeconomic studies; (ix) prices of
imilar medicines that are registered in KSA; and (x) the proposed
rice by the manufacturer (Kaló et al., 2015; Qarain et al., 2009;
han et al., 2015; Business Monitor International (BMI), 2017h;
lrasheedy, et al., 2017; Hajed, 2020). The KSA basket comprises
0 countries (Kaló, et al., 2015; Qarain et al., 2009; Khan et al.,
015; Business Monitor International (BMI), 2017h; Alrasheedy,
t al., 2017; Holtorf et al., 2019; Hajed, 2020) and the ERP price
s the lowest in the basket (Kaló, et al., 2015; Khan et al., 2015;
oltorf et al., 2019). Price revisions take place every five years at
roduct registration renewal (Khan et al., 2015).
In the UAE, ERP is used for price setting of imported in-patent
harmaceuticals and generics, except for pricing of wholly locally
anufactured generics. Price sources include official websites and
rices submitted by manufacturers. There are 18 countries in
he UAE basket, largely composed of European and neighbour-
ng countries to the UAE (Qarain et al., 2009; Espin et al., 2011;
buelkhair, et al., 2012; United Arab Emirates Ministry of Health
nd Prevention, 2018). Ex-factory, import, and CIF prices are col-
ected from basket countries (Kaló, et al., 2015; Qarain et al.,
009; Espin et al., 2011; Holtorf et al., 2019; United Arab Emirates
inistry of Health and Prevention, 2018) and the reference price
s the basket median (Kaló, et al., 2015; United Arab Emirates
inistry of Health and Prevention, 2018). Two types of price revi-
ions occur in the UAE (United Arab Emirates Ministry of Health and
revention, 2018): periodic reviews occur every five years along
ith renewal of product registration, under which all innovative
roduct prices are revised; exceptional price revisions are trig-
ered due to patent expiry, product changes, or upon request of
ational health authorities. In the UAE, there are price adjustments
o mitigate exchange rate fluctuations (Anonymous, 2018; Business
onitor International (BMI), 2017j).
Overall, in-patent pharmaceutical list prices across the study
ountries are set based on ERP (for both the retail and in-patient
arkets), yet interesting nuances exist at country level, including
he prices in COO and the GCC and the use of IRP as co-determinants
n price-setting (Kaló, et al., 2015; Qarain et al., 2009; ; Espin et al.,
011; Abuelkhair, et al., 2012; Khan et al., 2015; Ministry of Health
f the Sultanate of Oman and World Health Organization, 2011;
usiness Monitor International (BMI), 2017f, Business Monitor
nternational (BMI), 2017h; Alrasheedy, et al., 2017; Al Abbasi and
l Jalahma, 2017). With regards to reimbursement, ERP-derived
ist prices are reimbursed in the case of retail products, whereasPlease cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
n-patient products are covered based on tenders.
ERP is, thus, often combined with price assessments in the COO
Bahrain, Jordan, Lebanon, Oman, and KSA), or with IRP to derive
he product prices in the same therapeutic class (Bahrain, Oman, PRESS
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and Jordan for pharmaceuticals only available in the COO). Sev-
eral countries are now considering the therapeutic significance of
new pharmaceuticals (Bahrain and KSA) and (may) require phar-
macoeconomic studies during price-setting (Bahrain, Egypt, Jordan
and KSA). While the inclusion of pharmacoeconomic studies has
been documented in the literature, their consideration in prac-
tice is still unclear, perhaps with the exception of Egypt, where
they are used frequently to inform pricing and, mainly, coverage
decisions.
4.3. Alignment with the principles for best practice in ERP
We applied the 14 best practice principles to the study coun-
tries in order to determine each country’s degree of alignment with
these principles covering the objectives and scope of ERP systems,
administration and operations, methods used, and ERP implemen-
tation (see Table 4). Overall, none of the eleven countries satisfy all
14 principles, with most failing to implement an administratively
simple and transparent system or to use mean basket prices. Most
countries have large baskets and use the lowest basket price, reduc-
ing administrative simplicity. Because ERP is often designed as an
administratively driven process, many of its forms in the MENA
region exclude active stakeholder participation. Many of the coun-
tries in the region revise prices if their exchange rate fluctuates or
if prices change in basket countries in order to capitalise on the
possibility of further price diminution.
With few exceptions, it appears that the key objective of ERP
across MENA countries is to satisfy cost containment objectives
by benchmarking against the lowest list prices from inherently
diverse and large ERP baskets. The question, of course, is whether
this objective can be satisfied. List prices, that form the basis
of ERP calculation, for most new products are no longer rep-
resentative of net or transaction prices as reference countries
routinely resort to risk-sharing agreements (RSAs), confidential dis-
counting and negotiations to ensure the cost of new products is
affordable to them (Kanavos et al., 2020). This necessitates rel-
evant systems of value assessment, risk sharing and negotiation
to be in place, all of which are currently missing from the MENA
region.
While value assessment systems still remain aspirational across
the MENA region there are trends towards the adoption of HTA
either explicitly or implicitly, such as the recent policy on uni-
versal health coverage in Egypt (Ministry of Planning Monitoring
and Administrative Reform (Egypt), 2016) and KSA’s Vision 2030
(Kingdom of Saudi Arabia, 2020). Meanwhile, the impact of ERP
can be distorting as artificial benchmarks are created and there
is no meaningful notion of local value assessment of new prod-
ucts and their implications or importance in the countries in which
they are introduced. Consequently, ERP on its own, may  not be
the optimum pricing policy for achieving competitive, appropriate
and affordable price levels, compared to a more dynamic pricing
policy, which allows an expression of value in their national con-
text.
The decision-making community’s awareness of and response
to international implications of ERP differs between MENA
countries. In some cases, there is awareness of international impli-
cations, but these are not taken into consideration (e.g. the UAE,
Egypt, Morocco, and Jordan) (Anonymous, 2018). In other cases, pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
decision-makers are aware of the international implications of ERP
and attempt to mitigate them, (e.g. Algeria, where attempts are in
place to designing a legal mechanism to determine two  prices, a list



































































































































































√ × N/A × × ×1 ×1 ×1,2 √ × ×1 × × ×
Bahrain 47,212 × √ N/A √ × √ √ × √ × √ ×1 × ×
Egypt  12,390 × × N/A × ×1 ×1 × × × × ×1 ×1 × √
Jordan 9,348
√ √∼ N/A √ √∼ √ × × √ √3 × √ × ×
Kuwait  73,705 × - N/A √ √ √ × × × × - × × ×
Lebanon 13,058
√ × N/A √ × √ × ×1,2 × × √ √ × ×
Morocco 8,587
√ × N/A √ √ √ √ × √ × √ √ × √
Oman 41,435 - × N/A √ - - ×1 - √ × - - × ×
Qatar  126,598 × √ N/A √ × √ √ × × × √ √ × ×
Saudi  Arabia 55,120 × √ N/A × × √ × × √ × √ √ √ ×
UAE  74,943 × √∼ N/A √ × √ √ × √ √3 √ √ √ ×
Notes:1 Primary and secondary data collection and triangulation with multiple sources suggest this criterion is not met.





‘×’ = does not satisfy.
‘
√∼’  = partially satisfies.
‘-’ = no evidence.
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. Discussion
Our analysis of MENA country ERP systems presents a number
f lessons for policy. First, across the region, ERP informs pric-
ng decisions, which, in turn, inform coverage and reimbursement.
echanisms, such as negotiation processes and innovative con-
racting, particularly through the use of risk sharing, aiming to
ssess value whilst mitigating the high cost of new medicines, are
bsent.
Second, although there is no formal value assessment or explicit
TA system in operation in any of the MENA countries, three of
he countries undertake ad hoc economic evaluations of some in-
atent pharmaceuticals. Although this is done in an unsystematic
anner, there are trends towards these assessments, such as the
ecently passed legislation on universal health insurance coverage
n Egypt and KSA’s Vision 2030, where mention of HTA and broader
fficiency criteria are made.
Third, ERP systems may  depend on the list prices for many new
roducts from MENA reference basket countries, which may  not
e reflective of net prices (Gill et al., 2019; Kanavos et al., 2020).
n addition, the type of comparator prices used to inform the pric-
ng of pharmaceuticals in ERP include combinations of ex-factory,
holesale, retail or CIF prices. All countries besides Egypt, Kuwait,
ebanon, and Qatar employ ex-factory prices in their ERP sys-
ems. In Algeria, Egypt, Jordan, Lebanon, Morocco, Oman, Qatar,
nd the UAE, the responsibility for providing information for pric-
ng decisions to the competent authority rests with pharmaceutical
anufacturers (Espin et al., 2011; Anonymous, 2018). In Qatar,
onfidential pricing information on GCC CIF prices is also used
Anonymous, 2018). None of the study countries use mean prices;
ordan and the UAE use median prices and Morocco uses the aver-
ge only for existing products and selects the lowest price for newly
aunched products, while all other countries use the lowest price
n their respective basket.
Fourth, the patterns identified indicate that the higher the coun-
ry’s income per capita, the greater its adherence to best practice
rinciples. Despite this observation, the pursuit of administrative
implicity, appropriate country selection (based on comparable
ncome levels or levels of economic development), and use of mean
rices remain an elusive target in the region, with few exceptions.
he findings from primary research suggest that administrative
rocesses are complex and resource-intensive in much of the region
particularly in Algeria, Egypt, and KSA), in part resulting from the
ntensity of information required because of large basket sizes and
e-pricing frequencies. Additionally, very often, low- or middle-
ncome countries are included in reference baskets, which results
n prices declining continuously (Kanavos et al., 2018).
Fifth, few countries have made improvements to their ERP sys-
ems in recent years; notable exceptions are the UAE and KSA which
ave implemented provisions in line with several best practice
rinciples, such as respecting patent status, focusing on in-patent
rugs, avoiding the use of exchange rate volatility as a means
f price reduction, minimising price revision frequencies, enable
ppeals, and using ex-factory prices.
From a health care system perspective, an ERP system does not
ecessarily reflect the benefit arising from innovative therapies.
his is due to the design characteristics of ERP: first, while the ref-
rence baskets in many of the study countries include countries
hat use HTA mechanisms to inform price-setting, the use of the
owest price, effectively negates the input from these countries toPlease cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
e used. Second, patent expiries in reference countries and con-
omitant price reductions in these may  relate to patent status of
 particular product and the differences in the expiry of patent
erms across settings. It is possible for patents to expire first in PRESS
cy xxx (2020) xxx–xxx 11
several reference countries with prices declining due to generic
competition or the imposition of administrative measures (e.g.
mandatory price decrease); referent countries may  want to cap-
italise on that despite the product still being under patent in their
markets. Third, although price adjustments can be implemented
to account for exchange rate fluctuations, countries tend not to
account for dynamic exchange rate changes or reference country
wealth differences, especially if countries with stronger currencies
or higher incomes per capita are used as reference. Often, exchange
rates used are unrealistic and can offer a significant discount to
newly launched products upon entry, resulting in launch delays or
product shortages for products that have already been launched
(Kanavos et al., 2020). Only Jordan, Lebanon, Morocco, Qatar, KSA
and the UAE use techniques such as accounting for exchange rate
moving averages (Lebanon), or using a single currency to prevent
currency fluctuations (Qatar, Jordan) (Anonymous, 2018; Ammar,
2009). Fourth, re-pricing should be selective in order to create a
stable price environment that encourages the launch of new prod-
ucts. If ERP takes place biannually and the lowest in the basket is
selected, a race towards the bottom is almost certainly the outcome.
In principle, re-pricing in most study countries occurs every three to
five years from a statutory perspective, leading to the least possible
disruption or instability, unless prices change in basket countries
or exchange rates fluctuate, in which case referrent countries are
in a constant struggle to update list prices. Only KSA and UAE con-
form to the principle of ’infrequent re-pricing’ in the strict sense,
while, elsewhere, re-pricing can be triggered if prices change in key
basket countries (Algeria, Bahrain, Jordan, Kuwait, Morocco, and
Qatar), if exchange rates fluctuate (Morocco, Jordan), in response
to packaging changes (Morocco), or in response to manufacturing
site changes, and upon manufacturer requests (Bahrain) (Al Abbasi
and Al Jalahma, 2017).
Although requesting the same price in lower income markets
as in higher income markets could lead to in-patent pharmaceu-
ticals becoming excessively expensive in low and middle income
countries (LMICs), ERP per se does not definitively impact phar-
maceutical affordability in LMICs unless combined with other tools
that address this policy concern. If, as appears to be the case in
most MENA countries, ERP results in a price that is reimbursed by
the countries concerned without further action on reimbursement
negotiation, then, unavoidably, questions arise about the extent to
which list prices are affordable, particularly among some of the
lower income countries in the region. Additionally, an inflexible
pricing system which ‘borrows’ prices from other settings, with-
out further elaboration or negotiation, may  delay launches in those
countries or even deter price approval, and consequently, market
entry.
Given the nature of ERP, broader international implications,
such as price convergence and spill-over effects due to launch
delays, are to be expected. ERP policies adopted by MENA countries
lead to new, in-patent pharmaceutical product price convergence
between countries of different economic status (Kaló, et al., 2015).
The GCC price harmonisation process is leading to downward price
convergence as the process is designed to reduce pharmaceuti-
cal prices in the GCC and the broader MENA region (Business
Monitor International (BMI), 2017g), with Egypt, Jordan and Algeria
referencing GCC countries (Business Monitor International (BMI),
2017g). Evidence shows that ERP may  delay new product launch
because many new pharmaceutical products are not launched or
remain unapproved until reference countries have determined
their prices (Kaló, et al., 2015). The exception to this was the UAE,
which used a fast track pricing process, whereby it would only ref- pharmaceuticals in the Middle East and North Africa: Is external
://doi.org/10.1016/j.healthpol.2020.07.017
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.1. Limitations
Our analysis is not without limitations. First, although the attri-
utions made to the 14 best practice principles were based on
vidence obtained from local MoH  and expert surveys and inter-
iews, they remain subjective, but are based on triangulation from
ll available sources. Second, the literature review relied on sources
imited to the English language and relevant studies published in
ther languages, if they exist, unavoidably have been excluded;
uture research can address this gap. Finally, given pharmaceutical
ricing policies are constantly changing and updated, the evidence
resented in this study will not reflect the future policy landscape,
ut is a good benchmark at this point in time.
. Policy implications
Two key policy implications arise from the analysis and with
egards to pharmaceutical pricing and reimbursement in the MENA
egion: first, there is a need to reform ERP systems over the mid-
o long-term in order for them to become more effective and effi-
ient pricing tools as well as encourage and deliver affordable
rices where these are needed; and, second, there is also a need
o establish more formalised arrangements around clinical benefit
nd value assessment in order for these to be conducted locally and
ith a view to ultimately replacing ERP over the long-term.
Our analysis suggests that a number of improvements can be
ade to MENA ERP systems by prioritising certain design ele-
ents, which are more amenable to change in the short-run. These
nclude: (a) improvements in basket country selection, both in
erms of the number of countries in the basket and the country
election criteria; (b) improvements in price revision frequencies in
any of the study countries; (c) use of publicly available ex-factory
rices to obtain mean (or median) prices from the basket, while
ealth adjustments based on differential GDP per capita between
asket countries and referent country can be used if the former are
ignificantly wealthier than the latter; and (d) use ERP for in-patent
roducts only.
Beyond reforming the design elements raised above, MENA
ountries should also focus on longer-term reform aspects of their
ndividual pricing systems; for example, they should recognise and
ccount for the international implications of ERP; equally, they
hould not rely solely on ERP to inform pricing decisions, echoing
rends seen elsewhere, where ERP is not the centrepiece in pharma-
eutical pricing policy (Fontrier et al., 2019; Kanavos et al., 2020),
ut is used as a supplement to a range of other tools (e.g. HTA,
isk sharing agreements (RSAs)) to arrive at affordable prices and
rovides the starting point for reimbursement negotiations. Con-
equently, reimbursement systems may  need to be re-calibrated
iving emphasis on price negotiation and value assessment based
n local rules.
Recent trends in the region have included considerations relat-
ng to the adoption and implementation of HTA. Both Egypt
Ministry of Planning Monitoring and Administrative Reform
Egypt), 2016; ISPOR, 2019) and Kingdom of Saudi Arabia, 2020;
l-Omar et al., 2019) aspire to introduce such mechanisms while
ebanon and Morocco reportedly conduct token value assessments
n some cases (Anonymous, 2018). As the use of health economics
nd other tools, including innovative contracting and RSAs, is very
imited in MENA countries, the transition from a command-and-
ontrol system, such as ERP, to a value assessment system based
n HTA principles, requires the fulfilment of certain prior actions,Please cite this article in press as: Kanavos P, et al. Pricing of in-patent
reference pricing implemented optimally? Health Policy (2020), https
ncluding: (a) a clear vision and roadmap for the incorporation of
TA in decision-making; (b) investment in human and physical
nfrastructure and data systems to support implementation; (c)
uilding the relevant institution(s), deciding where HTA fits into PRESS
cy xxx (2020) xxx–xxx
current health system structures and how it interacts with other
policy measures; (d) a period of piloting and learning; and (d) the
separation from the registration process for new pharmaceuticals.
Ultimately, the implementation of HTA principles requires a grad-
ual shift in policy-making mindset towards an environment which
is more transparent, collaborative, consultative, and is supportive
of innovation and investment.
7. Conclusions
Having proposed an analytical framework to examine salient
features of ERP systems, we undertook an assessment of how well
MENA country ERP systems adhered to international best practice
principles. ERP was shown to be the dominant pricing method for
in-patent as well as off-patent pharmaceuticals, but most ERP sys-
tems present design flaws. Some of these can be rectified through
incremental changes that require minimal intervention but have
lasting impact on the overall ERP system, while others may  require
long-term, sustainable change in systems, institutions and mind-
sets. If implemented, changes can lead to fairer and sustainable
pricing, a gradual shift towards value assessment conducted locally,
greater equity in access to health technologies and innovation in the
MENA region. While all MENA countries are looking to reform their
health systems, there is still room for significant improvements in
order to streamline fragmented sectors and improve access to care
and population health outcomes.
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